IRCT20200105046010N108尚未招募Unknown
In-vivo Bioequivalence Study of Ozanimod 0.92 mg Capsulesof The Test Drug (Torenzo 0.92 mg Caps., Abidi Pharma, Iran) in Compared with The Reference Drug (ZEPOSIA® 0.92 mg, Celgene, USA) In Iranian Healthy Volunteers
Abidi Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28) kg/m^2
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Ozanimod
研究者
相似试验
尚未招募
不适用
In-vivo Bioequivalence Test of FAROXY® tablet with brand OXYCONTIN drugs (Purdue Pharma LP, UKIn this study, the disease is not examined. Subject bioequivalence test and reference tablets OXYCONTIN studied.IRCT20200105046010N32Pharan shimi Pharmaceutical Company24
招募中
不适用
In- Vivo Bioequivalence study of Oxycodone tablet 40 mg Alborz Pharmed (LENITON® ER 40mg Tab.) with brand drugs (OLBETE® ER 40 mg Tab.,Purdue Pharma LP, UK) in Iranian healthy volunteersBio equivalence test.IRCT20200105046010N69Alborz Pharmed Pharmaceutical Co.24
招募中
不适用
Study of absorption and elimination rate of omeprazole 20 mg capsule in comparison with omeprazole brand capsules (Prilosec®).bioequivalence study.IRCT20200407046981N19Yas Kavir Meybod Pharmaceutical Company24
尚未招募
不适用
Study of absorption and elimination rate of omeprazole 10-mg Sachet in comparison with omeprazole brand Sachet (Nexium®).IRCT20200407046981N20Kimia Kala Razi Pharmaceutical Company24
已完成
不适用
Comparative bioequivalence study of the Omeprazole 10-mg Sachet manufactured by Nafas Zist Pharmed Pharmaceutical CompanyIRCT20130313012810N9afas Zist Pharmed Pharmaceutical Company24